Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — Investor Presentation (September 2026)
30 slides from Onward Medical's investor presentation, September 2026
Slide 1: Company Deck September 2026
Company Deck September 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be “forward-looking statements”. These forward- looking statements may be identified by the use of forward-looking terminology, includi
Slide 3: Company Overview
Company Overview
Slide 4: ONWARD Overview
Pioneering neuromodulation therapies to restore movement, function, and ONWARD Overview independence after SCI 3 differentiated technology platforms designed to deliver precise spinal cord stimulation Commercial Pivotal trial Clinical underway feasibility 10 FDA Breakthrough Device US & Europe studi
Slide 5: Unmet Need
Legacy standard-of-care Unmet Need approaches do not offer restoration after spinal cord injury (SCI) Devastating Prevalent Costly Not only paralysis & US & Europe1 Global2 $2.9M / €2.6M loss of sensation; Avg Lifetime Cost3 frequently also infection, ~650,000 ~9,000,000 (paraplegic) incontinence, b
Slide 6: Vision
Vision Empowered by independence, people with spinal cord injury will enjoy life in the ways that matter to them ONWARD Medical Company Deck 6
Slide 7: Growth Strategy
Focus first on near-term indications and path to profitability, then unlock multiple additional Growth Strategy indications and populations Phase 1 Phase 2 Focus ARCEX hand sensation & strength and Label and platform expansion ARCIM blood pressure instability Expected o1 Drive commercial uptake for
Slide 8: Technology and Evidence
Technology and Evidence
Slide 9: External Platform
One of TIME Magazine’s External system for non-invasive, programmed Best Inventions of 2024 stimulation of the spinal cord TAM External Platform $6.0B / €5.2B US & EU eligible population ~200,0001 (30% of SCI cases2) ARCEX® Therapy Programmed transcutaneous electrical stimulation to the spinal cord
Slide 10: Pivotal Trial Results ARCEX Therapy
Met all primary and secondary endpoints, highlighting safety and effectiveness in Pivotal Trial Results improving upper limb function after SCI1 (n=65, 14 trial sites globally) ARCEX Therapy 90% 87% 34 YEARS Improved strength or Reported Responders up to 34 function improvement in years post-injury
Slide 11: Implantable Platform
IPG and leads for direct, programmed stimulation of the spinal cord TAM $9.3B / €8.2B US & EU eligible population ~210,0001 (32% of SCI cases2) Implantable Platform myARCIM® App via ARCIM® Controller ARCIM® Lead Family ARCIM® PRO App via ARCIM® Programmer ARCIM® Neurostimulator (IPG) ARCIM® Hub Conf
Slide 12: Blood Pressure Unmet Need in SCI
Greater than 90% of patients treated for blood pressure instability continue to Blood Pressure experience symptoms Unmet Need in SCI Orthostatic Hypotension (OH) Autonomic Dysreflexia (AD) Low blood pressure tied to posture or postural Sudden, often dangerous rise in blood pressure in response to a
Slide 13: Clinical Progress
Clinical feasibility results show encouraging results; pivotal trial underway Clinical Progress Clinical feasibility results published in Nature and Nature Medicine, September 2025 + Prospective, randomized, sham-controlled and double-blinded study + Reduced hypotension symptoms + Up to 112 particip
Slide 14: Pivotal Trial Update Empower BP
Pivotal Trial Empower Update BP Pivotal Trial Underway 22 participants enrolled 14 clinical sites actively recruiting First patient implanted 12 2026 2027 2028 2029 US sites activated Enrollment and primary endpoint completion Follow-up Interim analysis Anticipated commercial launch As of Sep 2026 C
Slide 15: Pipeline Overview
Advancing pipeline with grant funding and investigator-initiated studies to ensure focus on Pipeline Overview two initial indications and targeted use of capital Pre-clinical Human PoC Clinical feasibility Detailed next Pivotal Commercial Eligible population Platform Indication FDA BDD1 Current stag
Slide 16: Next indication: Standing and walking
Next indication: Standing and walking TAM1 US & EU eligible population $10.6B / €9.4B ~240,0002 (36% of SCI cases ) 3 1 Estimate based on eligible population (see footnotes 2&3) multiplied by pricing in alignment with value in Confidential comparison to existing rehabilitation therapies; 2 Estimate
Slide 17: Expected Next Indication: Mobility
Ability to stand and walk restored in Expected Next 10 participants with chronic injuries; even those with AIS-A severity Indication: Mobility Clinically Incomplete Spinal Cord Injury Clinically Complete Spinal Cord Injury Note: For investigational use only ONWARD Medical Company Deck 17
Slide 18: SCI Mobility
Promising clinical feasibility study results for enabling ability to stand and walk in participants SCI Mobility with chronic spinal cord injuries Eligible population Key achievements to date ~240’0001 Published data in Nature demonstrating Unmet need the preliminary effectiveness of spinal cord sti
Slide 19: Think AI-Powered Implantable ARCBCI Brain Implant
ARCBCI Brain Implant Brain and spinal cord are reconnected by ONWARD Think AI-Powered DigitalBridge to restore ARCBCI thought-driven movement Wearable Data Station An intention to move originates in the brain Implantable Platform . Decode An AI algorithm translates that intention into instructions f
Slide 20: BCI Mobility & Upper Limb
Enabling thought-driven movement for SCI and stroke patients; already BCI Mobility & 7 humans implanted1 Upper Limb Eligible population Key achievements to date Expected first indication: First-in-human implant for mobility Mobility2 ~420’000 SCI in 2021 and first-in-human for Potential additional i
Slide 21: Commercial
Commercial
Slide 22: Targeting and Channel Strategy
Customer concentration allows us to build direct sales channel and establish enduring Targeting and and valuable relationships Channel Strategy US Europe ~530 CALL POINTS GEOGRAPHICAL FOCUS ~450 ~80 US and select European markets with sophisticated neurorehabilitation infrastructure, clinical partne
Slide 23: US Rehabilitation Clinic Importance
Current focus is SCI rehabilitation clinics which are central to ONWARD’s US Rehabilitation Clinic commercialization strategy Importance SCI CLINIC CLINIC HOME Clinics purchase ARCEX devices as Clinics prescribe home use for new Clinics refer patients to capital equipment and bill for or chronic pat
Slide 24: ARCEX Commercial Uptake
159 ARCEX Systems sold or under paid ARCEX Commercial evaluation in 1H 2026 Uptake # of units supplied 89 units > 130 US clinics 70 units penetrated 47 units > 150 clinics 40 units globally 20 units 10 units Q1 Q2 Q3 Q4 Q1 Q2 2025 2026 Limited US clinic Broad US clinic US home and launch commerciali
Slide 25: Corporate
Corporate
Slide 26: Leadership Team
Strong leadership and governance with the expertise to scale the company Leadership Team Representative leaders from each stakeholder group Management Board Dave Marver Ali Kiboro Sean Sciara Shari O’Quinn Rob ten Hoedt Tim Denison, Prof. Lucas Buchanan Vivian Riefberg Chief Executive Chief Financia
Slide 27: 2025 Achievements
Very strong execution across all elements of the organization 2025 Achievements Commercial launch Advancing pipeline Corporate Sold 117 ARCEX® Systems to > 80 US clinics Received FDA IDE approval for EMPOWER BP Raised over EUR 50M in equity in first year on the market pivotal study capital, anchored
Slide 28: Financial Profile
Strong shareholder base and access to capital Financial Profile Cap table Capital access Strategic investors & Long-only and specialist investors 3 listing venues US ADRs traded on NON-EXHAUSTIVE Brussels Ticker: ONWRY Global leader in the fields of prosthetics, orthotics and Amsterdam exoskeleton t
Slide 29: Upcoming Milestones and News Flow
Several important catalysts expected in the next 12 months Upcoming Milestones ARCEX ARCIM ARCBCI and News Flow ARCEX ARCEX ARCEX ARCEX First commercial clinic First commercial home First commercial clinic First commercial home sale (EU) use sale (US) sale (ROW) use sale (EU) Hand sensation & Hand s
Slide 30: Slide 30
ONWARD Medical — Investor Presentation (September 2026) on 6ix